Isocard (Isosorbide Mononitrate)

Isocard, a nitrate vasodilator, is indicated for conditions within the angina pectoris disease family.

• Angina pectoris: reduces frequency and severity of chest pain episodes.
• Chronic stable angina: improves exercise tolerance and decreases need for short‑acting nitrates.
• Prevention of angina attacks: provides long‑acting prophylaxis to maintain stable cardiac workload.

• Isosorbide Mononitrate is metabolized to release nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting increase in cyclic guanosine monophosphate (cGMP) leads to relaxation of arterial and venous smooth muscle, producing vasodilation. This effect lowers both preload and afterload, decreasing myocardial oxygen demand while enhancing coronary blood flow, thereby alleviating anginal symptoms. The drug’s long‑acting profile provides sustained hemodynamic benefit over 24 hours.

Isocard may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: throbbing pain often occurring shortly after dosing.
• Dizziness or light‑headedness: due to transient blood pressure reduction.
• Flushing: warm sensation and reddening of the skin.
• Nausea or abdominal discomfort: mild gastrointestinal upset.
• Palpitations: awareness of heartbeat irregularities.
• Hypotension: mild drop in blood pressure, especially when standing.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure fall causing fainting.
• Syncope: sudden loss of consciousness.
• Myocardial infarction: rare but possible cardiac event.
• Life‑threatening arrhythmias: abnormal heart rhythms requiring urgent care.
• Stevens‑Johnson syndrome or severe skin reactions: extensive rash or blistering.
• Anaphylaxis: acute allergic reaction with airway compromise.

Before prescribing Isocard, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiovascular assessment: evaluate blood pressure and heart failure status prior to initiation.
• Concomitant nitrate use: avoid combining with other nitrate preparations to prevent excessive vasodilation.
• PDE‑5 inhibitor caution: do not co‑administer with sildenafil, tadalafil or similar agents.
• Renal or hepatic impairment: adjust therapy and monitor for accumulation in patients with organ dysfunction.
• Orthostatic hypotension education: advise patients to rise slowly from sitting or lying positions.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Isocard can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Other nitrates (e.g., nitroglycerin): additive vasodilatory effect may cause severe hypotension.
• PDE‑5 inhibitors (e.g., sildenafil, tadalafil): risk of profound blood pressure reduction.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (ACE inhibitors, beta‑blockers, calcium channel blockers): may enhance blood pressure‑lowering effect.
• Diuretics: increase risk of orthostatic hypotension.
• Alcohol: can potentiate vasodilatory side effects.
• Antimicrobial agents (e.g., macrolides, fluoroquinolones): may affect metabolism and increase plasma levels.